Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 27, 2026.

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 20, 2026.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

A movement disorder specialist at Northwestern Medicine discussed developments in disease-modifying research, adaptive clinical trial designs, and evolving device-based therapies in Parkinson disease. [WATCH TIME: 5 minutes]

The FDA expands pitolisant, marketed as Wakix, to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making pitolisant the only nonscheduled option for excessive daytime sleepiness and cataplexy attacks.

Neurology experts highlighted ongoing developments in artificial intelligence applications, disease-modifying mechanisms, and genetic therapies expected to undergo evaluation. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 13, 2026.

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]

In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents for International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

Here's some of what is coming soon to NeurologyLive® this week.

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.